Opinion|Videos|August 6, 2024

FDA Approved Treatments: Topical Ruxolitinib and Vitiligo Management

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME